Skip to main content

Table 1 Characteristics of the studies included in the meta-analysis

From: Association between genetic polymorphisms in AURKA (rs2273535 and rs1047972) and breast cancer risk: a meta-analysis involving 37,221 subjects

First author

Year

Country

Ethnicity

Design

Genotyping medthod

Number(case/control)

SNP

HWE

Ruan [13]

2011

China

Asian

PB

TaqMan

1334/1568

rs2273535

0.76

Shi [14]

2011

Sweden

Caucasian

PB

TaqMan

763/1516

rs2273535

0.23

MARIE-GENICA [15]

2010

German

Caucasian

PB

MALDI-TOF

3137/5469

rs2273535

0.12

rs1047972

0.17

Couch [16]

2007

CIMBA

Mixed

PB

TaqMan

3884/3303

rs2273535

NA

Tchatchou [17]

2007

German

Caucasian

PB

TaqMan

727/819

rs2273535

0.60

Vidarsdottir [18]

2007

Iceland

Caucasian

NA

PCR-RFLP

759/653

rs2273535

0.07

Cox [19]

2006

USA

Caucasian

NA

TaqMan

1259/1742

rs2273535

0.31

rs1047972

0.70

Fletcher [20]

2006

UK

Caucasian

PB

PCR-RFLP

507/875

rs2273535

0.13

Ewart-Toland [21]

2005

USA

Mixed

PB

SnAPSHOT

898/448

rs2273535

0.81

Lo [22]

2005

China(Taiwan)

Asian

HB

TaqMan

709/1972

rs2273535

0.23

rs1047972

0.80

Dai [23]

2004

China

Asian

PB

TaqMan

1102/1188

rs2273535

0.07

rs1047972

0.68

Egan [24]

2004

USA

Caucasian

PB

Sequencing

941/830

rs2273535

0.31

rs1047972

0.68

Sun [25]

2004

China

Asian

HB

PCR-RFLP

520/520

rs2273535

0.11

  1. HWE: Hardy-Weinberg equilibrium; PB: population based; HB: hospital-based; NA: not available; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; MALDI-TOF MS: Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry; CIMBA: the Consortium of Investigators of Modifiers of BRCA1/2 including 16 clinic and population-based research studies and multicenter consortia.